BioNTech SE
DEEURBioNTech SE (US:BNTX) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- biontech.de
- Investor relations
- investors.biontech.de/de
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- MAINZ
- Management
- Ugur Sahin
- IPO
- 2019-10-10
- Shares outstanding
- 251.2 M as of 2026-03-27
- Market cap
- 22.1 B EUR
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Legal form
- SGST
- ISIN
- US09075V1026
- LEI
- 894500UZJ5LG1F8J1U58
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- loss
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- −6.83 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 1.071.18
- ROEROE (return on equity) is net income over the last 12 months divided by average shareholders' equity over those 12 months. It shows how much profit the company earns on every 100 dollars of capital. Consistently above 15% is a sign of a strong business, but a high ROE can also come from heavy debt or small equity after buybacks. One-off gains (sale of a business, revaluation, tax benefit) are excluded; «!» explains why the value differs from the reported one or is unreliable. Companies with negative equity have no ROE.
- −8.0%
- Payout ratioPayout ratio — what share of net income the company pays out as dividends. Calculated: dividends paid over the last 12 months ÷ net income for the same 12 months × 100%. Up to 60% — safe margin, 60–90% — borderline, over 90% — dividend at risk of a cut. «Loss» — the company pays without a profit.
- 0%
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- −476 M EUR
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
Debt 360 M EUR FCF −476 M EUR The years shown on the page use net debt: cash on hand can be used to repay debt at any time. - 360 M EURnegative FCF — not covered
- Earnings, FCF and dividends paid — for the 12 months to 30.09.2026 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. — Wikipedia
Exchanges and tickers
Candles
Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.
Dividends
Orange dashed line «ex» — the ex-date: to receive the payment you must hold the shares before this day (shares bought on this day or later come without the dividend). On this day the price often drops by roughly the dividend amount. Blue dashed line «$» — the payment date. Future dates (up to 45 days) are shown on the right on a grey background.
P/E
The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.
For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.
My position
Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.
Payout yield
The blue dashed curve with its own % scale on the left: for each day — the last payment amount divided by that day close price. That is, what percentage of the share price one payment makes: the price rises — the percentage falls, and vice versa; when the company changes the payment, the curve moves to the new amount. The annual yield is roughly this percentage times the number of payments per year.
Above each «$» mark — the percentage of that payment relative to the price on the payment day (for future ones — relative to the last price, marked «≈»). Only payments in the chart exchange currency are counted.
Dividends
| Ex-date | Payment | Amount | % | Type | Ticker |
|---|---|---|---|---|---|
| 2022-06-02 | — | 1.9328 EUR | 1.3/1.3 % | — | XETRA:22UA |
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| SAHIN UGUR MD (Chief Exe… | ≈15.59% | 39.43 M | 2026-09-30 |
| FMR, LLC | 2.99% | 7.57 M | 2026-06-30 |
| Primecap Management Comp… | 1.49% | 3.77 M | 2026-06-30 |
| Dodge & Cox Inc. | 1.45% | 3.68 M | 2026-06-30 |
| Fidelity Contrafund | 1.26% | 3.18 M | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 1% | 2.52 M | 2026-06-30 |
| Flossbach von Storch SE | 0.88% | 2.23 M | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.87% | 2.19 M | 2026-06-30 |
| T. Rowe Price Investment… | 0.82% | 2.07 M | 2026-06-30 |
| Blackrock Inc. | 0.73% | 1.85 M | 2026-06-30 |
| Temasek Holdings (Privat… | 0.6% | 1.51 M | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.52% | 1.32 M | 2026-06-30 |
| T. Rowe Price Mid-Cap Gr… | 0.4% | 1.02 M | 2026-06-30 |
| Logos Global Management… | 0.4% | 1.02 M | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.39% | 989 580 | 2026-08-31 |
| PRIMECAP Odyssey Funds-P… | 0.35% | 897 156 | 2026-07-31 |
| GSK plc | 0.35% | 889 824 | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.27% | 683 752 | 2026-08-31 |
| Fidelity Contrafund-Fide… | 0.27% | 683 065 | 2026-07-31 |
| Fidelity Investment Trus… | 0.26% | 660 800 | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.21% | 525 778 | 2026-06-30 |
| AT Impf | — | — | — |
| POETTING SIERK (Chief Op… | — | — | 2026-04-22 |
